Drugs for HER-2-positive Breast Cancer

Nonfiction, Health & Well Being, Medical, Medical Science, Pharmacology, Specialties, Oncology
Cover of the book Drugs for HER-2-positive Breast Cancer by , Springer Basel
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783034600941
Publisher: Springer Basel Publication: January 6, 2011
Imprint: Springer Language: English
Author:
ISBN: 9783034600941
Publisher: Springer Basel
Publication: January 6, 2011
Imprint: Springer
Language: English

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

More books from Springer Basel

Cover of the book Tamoxifen by
Cover of the book Infection, Immune Homeostasis and Immune Privilege by
Cover of the book Treatment of Cystic Fibrosis and Other Rare Lung Diseases by
Cover of the book Towards a General Theory of Classifications by
Cover of the book Human Medical Research by
Cover of the book Dynamische Systeme by
Cover of the book Isaac Newton's Temple of Solomon and his Reconstruction of Sacred Architecture by
Cover of the book And Yet It Is Heard by
Cover of the book GABA and Sleep by
Cover of the book Berichte zu Pflanzenschutzmitteln 2011 by
Cover of the book Berichte zur Resistenzmonitoringstudie 2009 by
Cover of the book Immunosenescence by
Cover of the book Counting Surfaces by
Cover of the book Problem-Solving Methods in Combinatorics by
Cover of the book Variable Lebesgue Spaces by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy